ClinicalTrials.gg
RecruitingNCT03947567Updated Apr 28, 2020

Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

A Phase 4 interventional study of Recombinant Human Coagulation FVIII in Hemophilia A, sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to male participants. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Planned enrollment
7th of 80
240 · median 54
Started
2019
with 5 others
Phase 4
11 of 93
5 open now
Primary completion
2025-04
later than 3 of 38 live
Registered
32nd of 93
by date
Lead sponsor
5 of 93
Sinocelltech Ltd.

Among the 93 studies in Hemophilia A with a site in China, this one is the 7th largest by planned enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2019, is one of 11 in phase 4, reaches primary completion later than 3 of the 38 other live ones, and was the 32nd registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, open-label, extension trial to evaluate the safety, efficacy of SCT800 in long term prophylaxis and on-demand treatment in patients with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from V1, on-demand treatment is given when bleeding episodes occur. The study period is 120 consecutive weeks.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients who are diagnosed with severe (laboratory tested FVIII:C \<2%) hemophilia A;
  • Patients Who Completed trial of SCT800-A302 or SCT800-A 303 and New PTP(previously treated patients)(Previously received FVIII prophylactic or bleeding treatment, have the relevant records and are verified to have accumulated exposures days( EDs) ≥150 days;
  • Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result \<0.6 BU(Bethesda unit)/mL);
  • The treatment records of at least 50EDs before screening can be obtained;
  • negative; if HIV positive, the viral load \<200 particles/uL or \<400,000 copies/mL, and HIV patients must satisfy >200/μL;
  • The patient or his guardian voluntarily signed the Form.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any coagulation factor VIII or any ; known allergy to bovine, rodent or hamster bovine;
  • Has a history or family history of blood coagulation factor VIII inhibitor;
  • Patients with other coagulation dysfunction diseases in addition to hemophilia A;
  • Patients with other diseases, alcoholism, drug abuse, mental disorders or intellectual disabilities;
  • Patients with other severe or clinical significant diseases verified by the investigator to be unable to benefit from the clinical study;
  • Patients who participated in other clinical studies within one month before the first drug administration (except FVIII trials) and patients who participated in other FVIII clinical trials after signing the Form;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Recombinant Human Coagulation FVIII

    Drug: Recombinant Human Coagulation FVIII

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of FVIII inhibitors

    The Nijmegen-Bethesda assay shall be used to monitor the production of FVIII inhibitors during the trial.

    Time frame: up to 120 weeks

Secondary outcomes

  1. Annualized Bleeding Rate

    Annualized Bleeding Rate(ABR) can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25)

    Time frame: up to 120 weeks

  2. FVIII incremental in-vivo recovery

    Incremental recovery is determined as the peak factor level recorded in the first hour after infusion and is reported as \[IU/ml\]/\[IU/kg\]

    Time frame: up to 120 weeks

  3. Bleeding event treatment efficacy

    The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved).

    Time frame: up to 120 weeks

07

Study locations

1 of 1 sites recruiting
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tianjin, China
    Recruiting
    • Renchi Yang · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Apr 2025, 68 months after the start.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's planned 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 13, 2019
StartActual
Jul 26, 2019
Primary completionEst.
Apr 1, 2025
CompletionEst.
Apr 1, 2025
Last update
Apr 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03947567
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
May 13, 2019
Start date
Jul 26, 2019
Primary completion
Apr 1, 2025 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Apr 28, 2020

Study contacts

Renchi Yang
Contact
rcyang65@163.com
13512078851
Feng Xu
Contact
Renchi Yang
principal investigator · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omfiloctocog alfa

Start the discussion